Role of Interleukin-7 in the Development of and Recovery from Radiation-Induced Lymphopenia: A Post-hoc Analysis of a Prospective Cohort
Hwa Kyung Byun, Seung Yeun Chung, Kyoung-Jin Kim, Jinsil Seong
Cancer Res Treat. 2021;53(4):962-972. Published online 2021 Jan 26 DOI: https://doi.org/10.4143/crt.2020.1053
Citations to this article as recorded by 
Radiation Therapy and Myeloid-Derived Suppressor Cells: Breaking Down Their Cancerous Partnership
Kyra M. Boorsma Bergerud, Matthew Berkseth, Drew M. Pardoll, Sudipto Ganguly, Lawrence R. Kleinberg, Jessica Lawrence, David J. Odde, David A. Largaespada, Stephanie A. Terezakis, Lindsey Sloan
International Journal of Radiation Oncology*Biology*Physics.2024; 119(1): 42. CrossRef
The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy
Aleksei A. Stepanenko, Anastasiia O. Sosnovtseva, Marat P. Valikhov, Anastasia A. Chernysheva, Olga V. Abramova, Victor A. Naumenko, Vladimir P. Chekhonin
Frontiers in Immunology.2024;[Epub] CrossRef
Compassionate use of recombinant human IL‐7‐hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma
Stephen Ahn, Jae‐Sung Park, Heewon Kim, Minkyu Heo, Young Chul Sung, Sin‐Soo Jeun
Cancer Medicine.2023; 12(6): 6778. CrossRef